Low-Dose Aspirin after an Episode of Haemorrhagic Stroke Is Associated with Improved Survival

Abstract

We aimed at investigating how antiplatelet drug use affected mortality in patients with a history of haemorrhagic stroke (HS). Thus, starting 30 days after an HS episode, we followed 1,004 patients with intracerebral haemorrhage (ICH) and 929 patients with subarachnoid haemorrhage (SAH) for a median of 6.4 years. We estimated the effect of time-dependent exposure to antiplatelets after HS on all-cause mortality. Cox proportional hazard models were used to compute adjusted hazard ratios (aHRs) and 95% confidence intervals (CI).

We found that current use of low-dose aspirin was associated with a 32% improved survival (aHR = 0.68; 95% CI: 0.53–0.88), with a similar association among ICH (aHR = 0.66; 95% CI: 0.49–0.89) and SAH (aHR = 0.61; 95% CI: 0.36–1.04) patients. A statistically significant improved survival associated with current use of low-dose aspirin during follow-up was only observed among individuals who used antithrombotic drugs in the year before the HS (prior use: aHR = 0.56; 95% CI: 0.39–0.80; non-prior use: aHR = 0.87; 95% CI: 0.61–1.24). Current use of clopidogrel was not associated with survival (aHR = 1.35; 95% CI: 0.88–2.08). Statin use was associated with improved survival (aHR = 0.38; 95% CI: 0.31–0.47). On the other hand, discontinuation of statins (aHR = 1.31; 95% CI: 1.02–1.68) or low-dose aspirin (aHR = 1.54; 95% CI: 1.21–1.97) was associated with decreased survival. In our study, use of low-dose aspirin after an episode of HS to reduce vascular risks is safe, particularly in patients who were on antithrombotic therapy before the episode. Our results suggest an improved survival associated with low-dose aspirin. This finding must be interpreted with care due to the observational nature of the study, and warrants further studies.

Keywords

intracranial haemorrhages - cohort studies - aspirin - mortality

• References

• 1 García-Rodríguez LA, Gaist D, Morton J, Cookson C, González-Pérez A. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology 2013; 81 (06) 566-574
• 2 González-Pérez A, Gaist D, Wallander MA, McFeat G, García-Rodríguez LA. Mortality after hemorrhagic stroke: data from general practice (The Health Improvement Network). Neurology 2013; 81 (06) 559-565
• 3 Roquer J, Vivanco Hidalgo RM, Ois A. , et al. Antithrombotic pretreatment increases very-early mortality in primary intracerebral hemorrhage. Neurology 2017; 88 (09) 885-891
• 4 Hemphill III JC, Greenberg SM, Anderson CS. , et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46 (07) 2032-2060
• 5 Weimar C, Benemann J, Terborg C, Walter U, Weber R, Diener HC. ; German Stroke Study Collaboration. Recurrent stroke after lobar and deep intracerebral hemorrhage: a hospital-based cohort study. Cerebrovasc Dis 2011; 32 (03) 283-288
• 6 Biffi A, Halpin A, Towfighi A. , et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010; 75 (08) 693-698
• 7 Chong BH, Chan KH, Pong V. , et al. Use of aspirin in Chinese after recovery from primary intracranial haemorrhage. Thromb Haemost 2012; 107 (02) 241-247
• 8 Flynn RW, MacDonald TM, Murray GD, MacWalter RS, Doney AS. Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage. Stroke 2010; 41 (11) 2606-2611
• 9 Viswanathan A, Rakich SM, Engel C. , et al. Antiplatelet use after intracerebral hemorrhage. Neurology 2006; 66 (02) 206-209
• 10 Gathier CS, Algra A, Rinkel GJ, van der Worp HB. Long-term outcome after anticoagulation-associated intracerebral haemorrhage with or without restarting antithrombotic therapy. Cerebrovasc Dis 2013; 36 (01) 33-37
• 11 Schmidt LB, Goertz S, Wohlfahrt J, Melbye M, Munch TN. Recurrent intracerebral hemorrhage: associations with comorbidities and medicine with antithrombotic effects. PLoS One 2016; 11 (11) e0166223
• 12 Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014; 85 (06) 660-667
• 13 Hansen BM, Nilsson OG, Anderson H, Norrving B, Säveland H, Lindgren A. Long term (13 years) prognosis after primary intracerebral haemorrhage: a prospective population based study of long term mortality, prognostic factors and causes of death. J Neurol Neurosurg Psychiatry 2013; 84 (10) 1150-1155
• 14 Ronkainen A, Niskanen M, Rinne J, Koivisto T, Hernesniemi J, Vapalahti M. Evidence for excess long-term mortality after treated subarachnoid hemorrhage. Stroke 2001; 32 (12) 2850-2853
• 15 Wermer MJ, Greebe P, Algra A, Rinkel GJ. Long-term mortality and vascular event risk after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2009; 80 (12) 1399-1401
• 16 Nieuwkamp DJ, de Wilde A, Wermer MJ, Algra A, Rinkel GJ. Long-term outcome after aneurysmal subarachnoid hemorrhage-risks of vascular events, death from cancer and all-cause death. J Neurol 2014; 261 (02) 309-315
• 17 Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41 (12) 2731-2738
• 18 Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
• 19 Gaist D, Wallander MA, González-Pérez A, García-Rodríguez LA. Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network. Pharmacoepidemiol Drug Saf 2013; 22 (02) 176-182
• 20 Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998; 51 (03) 690-694
• 21 Al-Shahi Salman R, Dennis MS. Antiplatelet therapy may be continued after intracerebral hemorrhage. Stroke 2014; 45 (10) 3149-3150
• 22 Abel J. Withdrawing life-extending drugs at the end of life. Prescriber 2013; 24: 17-20
• 23 Ostergaard K, Pottegård A, Hallas J, Bak S, dePont Christensen R, Gaist D. Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death: a cohort study. Neuroepidemiology 2014; 43 (01) 57-64
• 24 Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms. A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 132. Rockville, MD: Agency for Healthcare Research and Quality; 2015
• 25 Cha JK, Jeon HW, Kang MJ. ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Eur J Neurol 2008; 15 (12) 1304-1308